

News Releases

All Years



Search

GO

[Advanced Search](#)

May 18, 2020

Portola Pharmaceuticals Announces Virtual 2020 Annual Stockholder Meeting

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of...

May 14, 2020

U.S. Centers for Medicare & Medicaid Services (CMS) Proposes Extending New Technology Add-on Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa® for Third Year

- Reinforcing Breakthrough Innovation and Clinical Value of Andexxa, Proposed Extension Will Support Patient Access by Continuing to Provide Medicare Reimbursement in the Hospital Setting -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has proposed extending the New Technology Add-on Payment (NTAP) for Andexxa®...

May 11, 2020

Portola Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update

- Reached Agreement to be Acquired by Alexion; Transaction Expected to Close in Third Quarter -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended March 31, 2020, and provided a corporate update, including the Company's actions to...

May 5, 2020

Portola Pharmaceuticals Cancels First Quarter 2020 Financial Results Webcast and Conference Call Following Agreement to be Acquired by Alexion

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) (the "Company" or "Portola") today announced that it is cancelling its webcast and conference call to discuss the Company's financial results for the...

May 5, 2020

Alexion to Acquire Portola

- Expands and diversifies Alexion's hematology, neurology and critical care commercial portfolio with transformative Factor Xa inhibitor reversal agent -

BOSTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced today that they have entered into a...

May 1, 2020

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) announced today that on April 30, 2020, the Compensation Committee of the Board of Directors approved, effective as of April 30, 2020, the grant to...

Apr 23, 2020

Portola Pharmaceuticals to Announce First Quarter 2020 Financial Results on Monday, May 11, 2020

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended March 31, 2020, and...

Apr 7, 2020

Portola Pharmaceuticals Announces the Establishment of a Permanent J-code for Andexxa by the Centers for Medicare & Medicaid Services, Effective July 1, 2020

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that the Centers for Medicare & Medicaid Services (CMS) established a new permanent J-code for Andexxa® [coagulation factor Xa...

Apr 1, 2020

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) announced today that on March 31, 2020, the Compensation Committee of the Board of Directors approved, effective as of March 31, 2020, the grant to...

Mar 18, 2020

Portola Pharmaceuticals Announces Proactive Steps Supporting Public Health Efforts to Combat Coronavirus (COVID-19)

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced proactive steps the Company is taking in support of public health efforts to prevent further spread of coronavirus (or COVID-19) around...

Mar 16, 2020

Portola Pharmaceuticals Announces Results Demonstrating Andexxa® was Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds

Real-World Data Support Use of Andexxa Can Improve Outcomes

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new data reinforcing the value of Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only FDA-approved...

Mar 5, 2020

New Data Demonstrates Andexxa® Can Provide a Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa Inhibitors

- Analysis Projects Hospital Use of Andexxa with NTAP Reimbursement Can Reduce Cost Per Hospitalization by \$5,400 Compared to 4F-PCC -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the presentation of new data demonstrating that using Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo] to treat...

Mar 2, 2020

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) announced today that on February 28, 2020, the Compensation Committee of the Board of Directors approved, effective as of February 28, 2020, a grant...

Feb 26, 2020

Portola Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update

- Full-Year 2019 Andexxa®/Ondexxa® Net Product Revenues of \$111.5 Million -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the fourth quarter and full year ended December 31, 2019. "2019 was a year of significant accomplishments for..."

Feb 24, 2020

Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that the Company will participate in the following conferences in March. Cowen 40th Annual Health Care Conference on Tuesday, March...

Feb 12, 2020

Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26, 2020

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the fourth quarter and full year ended...

Feb 3, 2020

Portola Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President and Chief Medical Officer

- Brings to Portola 20 Years of Clinical Development and Approval Experience -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the appointment of Rajiv Patni, M.D., as executive vice president and chief medical officer, effective immediately. Dr. Patni brings...

Jan 9, 2020

Portola Announces Preliminary Full Year 2019 Andexxa Global Net Revenues of Approximately \$111 Million

- Fourth Quarter Net Revenues of Andexxa Expected to be Approximately \$28 Million Including \$4 Million in Fourth Quarter Sales from Ondexxya in Europe -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced preliminary unaudited Andexxa global net revenues for the fourth quarter and full year 2019. For the fourth quarter, the Company...

Dec 23, 2019

Portola Pharmaceuticals to Webcast Corporate Update on January 14, 2020

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that it will host an investor event to discuss expected corporate and product milestones in 2020. The event is scheduled to take place on

Dec 17, 2019

Portola Pharmaceuticals to Support New American Heart Association Initiative to Address Hemorrhagic Stroke

- American Heart Association Quality Improvement Project Promotes Patient Education and Physician Best Practices for Hemorrhagic Stroke -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced its support of the American Heart Association®/American Stroke Association's® newest initiative for enhanced awareness and...

Dec 9, 2019

Portola Pharmaceuticals Presents New Interim Data at the 61st ASH Meeting on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma

- Interim Phase 2a Data Demonstrate Improved Overall Response Rate in Combination with Rituximab -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in...

Dec 8, 2019

Portola Pharmaceuticals Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated T-Cell Malignancies

- Interim Results Demonstrate Good Tolerability and Clinical Response in Patients with

- Interim Results Demonstrate Good Tolerability and Clinical Response in Patients with Relapsed/Refractory PTCL and CTCL -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in...

Nov 15, 2019

Andexxa Highlighted as a First-Line Factor Xa Reversal Option by the American College of Emergency Physicians

- Recommendations from Multidisciplinary Expert Panel on Anticoagulant Reversal and Replacement Guidance Published in Annals of Emergency Medicine -

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that Annals of Emergency Medicine, the journal of the American College of Emergency Physicians (ACEP), published a multidisciplinary...

Nov 6, 2019

Portola Pharmaceuticals to Present Multiple Abstracts at the 61st American Society of Hematology (ASH) Annual Meeting

- Cerdulatinib Interim Phase 2a Data Highlight Efficacy and Safety Results in Patients with Heavily Pre-Treated T-Cell Malignancies and Follicular Lymphoma -

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, will...

Nov 5, 2019

Portola Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

- Andexxa®/Ondexxa® Net Product Revenues of \$35.7 million, a 32% Increase Over the Prior Quarter -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended September 30, 2019, and provided a corporate update. "We delivered another quarter of...

Nov 1, 2019

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) announced today that on October 31, 2019, the Compensation Committee of the Board of Directors approved, effective as of October 31, 2019, the grant...

Oct 28, 2019

Portola Pharmaceuticals Presents New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Acute Gastrointestinal Bleeding

- Effective Hemostasis Achieved in 82% of Evaluable Patients with Acute Gastrointestinal Bleeding -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the presentation of a new exploratory analysis of data from ANNEXA-4, the Company's Phase 3b/4 trial of its Factor Xa inhibitor...



Oct 15, 2019

Portola Pharmaceuticals to Announce Third Quarter 2019 Financial Results on Tuesday, November 5, 2019

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended September 30, 2019,...

Sep 19, 2019

Portola Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors

Portola Pharmaceuticals, Inc. (Nasdaq: PTLA) today announced the appointment of Ted W. Love, M.D., to its Board of Directors. Dr. Love is a recognized industry leader with more than 25 years of...

Aug 22, 2019

Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the Company will participate in the following conferences in September. Citi's 14th Annual Biotech Conference on Wednesday,...

Aug 13, 2019

Portola Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today announced the pricing of its underwritten public offering of 8,035,715 shares of its common stock at a price to the public of \$28.00 per share. In...

Aug 12, 2019

Portola Pharmaceuticals Announces Proposed Offering of Common Stock

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced plans to offer, subject to market and other conditions, \$200 million of its common stock in an underwritten public offering. The...

Aug 7, 2019

Portola Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update

- **Second Quarter Revenues of \$28.4 Million; Andexxa® Net Product Revenues Grow to \$27.1 Million**

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended June 30, 2019, and provided a corporate update. "This is our fifth consecutive quarter of...

Aug 6, 2019

Portola Launches European Sales of Ondexxa® (Andexanet Alfa) with First Orders in Europe

- **Expands Patient Access to the First and Only Factor Xa Reversal Agent Approved in Europe for Life-Threatening Bleeds Associated with the Use of Rivaroxaban or Apixaban** -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the Company's first sales of Ondexxa® (andexanet alfa) in Europe. These sales mark the initiation of commercial access in Europe to...

Aug 5, 2019

U.S. Centers for Medicare and Medicaid Services (CMS) Increases New Technology Add-On Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa

- **Add-on Payment Increased from 50 to 65 Percent; Supports Patient Access by Providing Additional Medicare Reimbursement in the Hospital Setting** -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has increased the maximum reimbursement amount for the New Technology...

Jul 17, 2019

Portola Pharmaceuticals to Announce Second Quarter 2019 Financial Results on Wednesday,

August 7, 2019

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webinar and conference call to discuss the Company's financial results for the quarter ended June 30, 2019, and...

Jul 8, 2019

Portola Pharmaceuticals Presents New In Vitro Data Demonstrating that Four-Factor Prothrombin Complex Concentrates (4F-PCCs) Had No Direct Effect on Inhibition of Thrombin

Generation by Factor Xa Inhibitors

- Data Presented at the Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH 2019) -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new invitro data establishing the relationship between concentrations of the direct oral anticoagulants (DOACs) apixaban and...

Jun 19, 2019

Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma

- Interim Phase 2a Data Highlight Efficacy and Safety Results of Cerdulatinib Alone and in Combination with Rituximab -

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in...

May 28, 2019

Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

May 28, 2019 PDF Version SOUTH SAN FRANCISCO, Calif., May 28, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola's president and...

May 22, 2019

Portola Pharmaceuticals Announces New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Spontaneous (Non-Traumatic) Intracranial Hemorrhage

- Excellent or Good Hemostasis Achieved in 79% of Evaluable Patients with Spontaneous Intracranial Hemorrhage -

SOUTH SAN FRANCISCO, Calif., May 22, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the presentation of a new analysis of data from an important subgroup...

May 8, 2019

Portola Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update

- First Quarter Revenues of \$22.2 Million; Andexxa® Product Revenues Grow 45% to \$20.3 Million -

SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended March 31, 2019 and...

Apr 26, 2019

European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals' Ondexxa™ (andexanet alfa), the First and Only Antidote for the Reversal of Factor Xa Inhibitors

- Major Advance in the Treatment of European Factor Xa Inhibitor Patients Hospitalized with Life-Threatening Bleeding -

SOUTH SAN FRANCISCO, Calif., April 26, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the European Commission (EC) has granted conditional Marketing...

Apr 24, 2019

Portola Pharmaceuticals Announces Retirement of Dr. John Curnutte, Executive Vice President and Head of Research and Development

SOUTH SAN FRANCISCO, Calif., April 24, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that John Curnutte, M.D., Ph.D., Executive Vice President and Head of...

Apr 17, 2019

Portola Pharmaceuticals to Announce First Quarter 2019 Financial Results on Wednesday, May 8, 2019

SOUTH SAN FRANCISCO, Calif., April 17, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company'

Mar 20, 2019

Portola Pharmaceuticals' Co-Founder Dr. Charles Homcy Retires from the Company's Board of Directors

SOUTH SAN FRANCISCO, Calif., March 20, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that on March 15, 2019 Charles Homcy, M.D., informed the Board of his...

Mar 6, 2019

Portola Pharmaceuticals to Webcast Presentation at Cowen and Company's 39th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola's president and chief executive...

Mar 1, 2019

European CHMP Adopts Positive Opinion on Ondexxys™ (andexanet alfa) Portola Pharmaceuticals' Factor Xa Inhibitor Reversal Agent

SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...

Mar 1, 2019

Portola Pharmaceuticals Enters into \$125 Million Loan Agreement with HealthCare Royalty Partners and Athyrium Capital Management

Agreement Provides Financial Flexibility for the Ongoing Commercialization of Andexxa® and Launch Preparations in Europe

SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that it has entered into a \$125 million loan agreement with...

Mar 1, 2019

Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

- Fourth Quarter Andexxa® Revenues of \$14.0 Million; Third Consecutive Quarter of Strong Revenues -

SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three and twelve months ended December 31,...

Feb 7, 2019

Portola Pharmaceuticals Announces Full Results from the ANNEXA-4 Study of the Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Life-Threatening Bleeding

- Excellent or Good Hemostasis Achieved in 82 Percent of Evaluable Patients -

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced full results from ANNEXA-4, the Company's Phase 3b/4 trial of its...

Feb 1, 2019

Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on Friday, March 1, 2019

SOUTH SAN FRANCISCO, Calif., Feb. 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the...

Jan 30, 2019

Portola Pharmaceuticals to Present Full Results from the ANNEXA-4 Study of Andexxa During a Late-Breaking Oral Presentation at the International Stroke Conference 2019

Results to be presented on Thursday, February 7, 2019 at 11:36 a.m. HST/4:36 p.m. EST

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that full results from the Company's ANNEXA-4 study of Andexxa®...

Jan 28, 2019

Portola Pharmaceuticals Appoints Sheldon Koenig as Chief Commercial Officer

Brings to Portola 30 Years' Commercial Experience and Key Therapeutic Area Launch Expertise

SOUTH SAN FRANCISCO, Calif., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the appointment of Sheldon Koenig as executive vice president and...

Dec 31, 2018

U.S. Food and Drug Administration Approves Portola Pharmaceuticals' Prior Approval Supplement for Andexxa® Generation 2 Manufacturing Process

- Expands Patient Access to Andexxa, the First and Only Antidote for Reversal of the Factor Xa Inhibitors Rivaroxaban or Apixaban -

SOUTH SAN FRANCISCO, Calif., Dec. 31, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the U.S. Food and Drug Administration (FDA) has approved the...

Dec 18, 2018

Portola Pharmaceuticals to Webcast Corporate Update on January 8, 2019

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola's president and chief executive officer,...

Dec 11, 2018

CHMP Extends Review Period for Portola Pharmaceuticals' Ondexxya™ (andexanet alfa)

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...

Dec 3, 2018

Updated Interim Results from Ongoing Phase 2a Study of Portola Pharmaceuticals' Oral Syk/JAK Inhibitor Cerdulatinib Continues to Demonstrate Clinical Responses in Heavily Pre-Treated T-Cell Malignancies

- Early Signs of Durable Response Across Patients with Relapsed/Refractory PTCL -

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced updated interim results from the Company's ongoing Phase 2a study of...

Nov 7, 2018

Portola Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

- Third Quarter Andexxa Product Revenues of \$7.7 Million -

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended September 30, 2018 and...

Nov 6, 2018

Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the Company will participate in the following investor...

Nov 1, 2018

Portola Pharmaceuticals to Present New Interim Phase 2 Results for Cerdulatinib During an Oral Session at the 60th American Society of Hematology (ASH) Annual Meeting

- Differentiated Syk/JAK Inhibitor Studied in Patients with Heavily Pre-Treated T-Cell Malignancies -

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that new interim results from the Company's ongoing Phase 2a study...

Nov 1, 2018

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) announced today that on October 26, 2018, the Compensation Committee of the Board of...

Oct 23, 2018

Portola Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Wednesday, November 7, 2018

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that it will host a webcast and conference call to discuss the...

Oct 9, 2018

Portola Pharmaceuticals Supports 2018 World Thrombosis Day Campaign to Raise Awareness of Blood Clots as an Urgent and Growing Health Crisis

Highlights Proactive Risk Assessment in Hospitals as Opportunity to Optimize Patient Outcomes

SOUTH SAN FRANCISCO, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced its 2018 partnership with the World Thrombosis Day campaign to help...

Sep 25, 2018

Portola Pharmaceuticals Receives FDA Orphan Drug Designation for Cerdulatinib, an Oral Syk/JAK Inhibitor for the Treatment of Peripheral T-Cell Lymphoma

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq: PTLA) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug...

Sep 20, 2018

Portola Pharmaceuticals Names Scott Garland President and Chief Executive Officer

- Relypsa president and former Exelixis chief commercial officer brings significant commercial and operational expertise -

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the appointment of industry veteran Scott Garland as president and...

Sep 11, 2018

U.S. FDA Assigns PDUFA Date to Portola Pharmaceuticals' Prior Approval Supplement for the Large-Scale Generation 2 Andexxa Process

Action Date Set for December 31, 2018

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged

(Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged...

Sep 7, 2018

Portola Pharmaceuticals Announces Executive Leadership Change

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that Tao Fu, chief commercial officer, has resigned effective...

Sep 5, 2018

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on August 31, 2018, the Compensation Committee of the Board of...

Aug 31, 2018

Portola Pharmaceuticals Submits Prior Approval Supplement to U.S. FDA for Large-Scale Generation 2 Andexxa Process

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced the submission of a prior approval supplement (PAS) to the U.S. Food...

Aug 30, 2018

Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the company will participate in the following conferences in...

Aug 9, 2018

Portola Pharmaceuticals Appoints Ernie Meyer as Executive Vice President and Chief Human Resources Officer

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced the appointment of Ernie Meyer as executive vice president and chief...

Aug 9, 2018

Portola Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update

- Conference Call Today at 8:30 a.m. ET -

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today reported financial results for the three months ended June 30, 2018 and provided...

Aug 3, 2018

U.S. Centers for Medicare and Medicaid Services (CMS) Grants New Technology Add-On Payment for Portola Pharmaceuticals' Andexxa

- Add-on payment to support patient access by providing additional Medicare reimbursement in the hospital setting -

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has...

Aug 2, 2018

Portola Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 9, 2018

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that it will host a webcast and conference call to discuss the...

Jul 27, 2018

European CHMP Maintains Negative Opinion on Portola Pharmaceuticals' Betrixaban Following Appeal

SOUTH SAN FRANCISCO, Calif., July 27, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...

Jul 3, 2018

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., July 03, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on June 27, 2018, the Compensation Committee of the Board of...

Jun 25, 2018

Portola Pharmaceuticals Appoints 30-Year Industry Veteran Glenn Brame as Senior Vice President of Technical Operations

SOUTH SAN FRANCISCO, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced the appointment of Glenn Brame as senior vice president of technical...

Jun 5, 2018

Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the company will present at the following conferences in June:...

Jun 4, 2018

New Interim Phase 2a Study Results Demonstrate Broad Clinical Activity of Portola Pharmaceuticals' Oral SYK/JAK Inhibitor Cerdulatinib

- Differentiated SYK-JAK Inhibitor Shows Efficacy in Patients with Heavily Pre-Treated B- and T-Cell Malignancies -

SOUTH SAN FRANCISCO, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced new interim results from the Company's ongoing Phase 2a study of...

Jun 4, 2018

Portola Pharmaceuticals Announces Retirement of CEO Bill Lis in 2018

SOUTH SAN FRANCISCO, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that William Lis has informed the Board of Directors of his plans to...

May 24, 2018

Portola Pharmaceuticals Receives \$100 Million Milestone Payment from HealthCare Royalty Partners for FDA Approval of Andexxa®


SOUTH SAN FRANCISCO, Calif., May 24, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the company has received a \$100 million milestone payment from...

May 9, 2018

Portola Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update

-- Conference Call Today at 4:30 p.m. ET --

SOUTH SAN FRANCISCO, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today reported financial results for the three months ended March 31, 2018 and provided...



U.S. FDA Approves Portola Pharmaceuticals' Andexxa®, First and Only Antidote for the Reversal of Factor Xa Inhibitors

- Breakthrough Product is a Major Advance in the Treatment of Patients Hospitalized with Life-Threatening Bleeding -

SOUTH SAN FRANCISCO, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA) has approved Andexxa®...

 [Photos \(2\)](#)

Apr 30, 2018

Portola Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018

SOUTH SAN FRANCISCO, Calif., April 30, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that it will host a webcast and conference call to discuss the...

Apr 25, 2018

Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

- Novel Oral SYK/JAK Inhibitor for Relapsed/Refractory B-cell and T-cell Cancers -

SOUTH SAN FRANCISCO, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that new interim results from the Company's ongoing Phase 2a study...

Apr 4, 2018

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., April 04, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on March 29, 2018, the Compensation Committee of the Board of...

Mar 23, 2018

Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European Union

SOUTH SAN FRANCISCO, Calif., March 23, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...

Mar 12, 2018

Portola Pharmaceuticals Appoints Biotech Legal Veteran John Moriarty as Executive Vice President and General Counsel

SOUTH SAN FRANCISCO, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced the appointment of John B. Moriarty, J.D., as executive vice president...

Mar 12, 2018

Portola Pharmaceuticals Announces New Interim Results from Ongoing ANNEXA-4 Study of Factor Xa Inhibitor Reversal Agent Andexxa® (Andexanet Alfa) in Patients with Life-Threatening Bleeding

- Excellent or Good Hemostasis Achieved in 83 Percent of Patients; Thrombotic Events Consistent with High Background Thrombotic Risk -

SOUTH SAN FRANCISCO, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced new interim results from ANNEXA-4, the Company's ongoing Phase 3b/4...

Mar 6, 2018

Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that Bill Lis, chief executive officer, will present at the following...

Mar 5, 2018

Portola Pharmaceuticals to Host Webcast Event and Conference Call at ACC.18 to Discuss Late-Breaking Oral Presentation Highlighting New Interim Data for Andexanet Alfa

Event Scheduled for Monday, March 12, 2018 at 12:30 p.m. ET

SOUTH SAN FRANCISCO, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that it will host a live audio webcast and conference call on Monday,...

Feb 28, 2018

Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update

--Conference Call Today at 4:30 p.m. ET--

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today reported financial results for the fourth quarter and full year ended December...

Feb 20, 2018

Portola Pharmaceuticals Announces Results of CHMP Oral Explanations for Andexanet Alfa and Betrixaban

Company to Host Conference Call on Tuesday, February 20, 2018, at 5:00 p.m. ET

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...

Feb 15, 2018

Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Wednesday, February 28, 2018

SOUTH SAN FRANCISCO, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that it will host a webcast and conference call to discuss the...

Jan 22, 2018

Portola Pharmaceuticals Announces Acceptance of Late-Breaker Abstract Highlighting New Data for Andexanet Alfa at ACC.18

SOUTH SAN FRANCISCO, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that an abstract detailing interim results from the Company's ongoing...

Dec 22, 2017

Portola Pharmaceuticals to Webcast Corporate Update on January 9, 2018

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that it will host an investor event to discuss expected corporate and...

Dec 22, 2017

Portola Pharmaceuticals Provides Update on Biologics License Application (BLA) for AndexXa® (andexanet alfa)

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA) will extend its review...

Dec 19, 2017

U.S. Food and Drug Administration Approves Prior Approval Supplement for Commercial Launch of Portola Pharmaceuticals' Novel Oral Anticoagulant Bevyxxa® (betrixaban)

Bevyxxa Available to Patients in January 2018

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that the U.S. Food and Drug Administration (FDA) has approved the...

Dec 12, 2017

Portola Pharmaceuticals Provides Update on European Marketing Authorization Application for Betrixaban

South San Francisco, Calif., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...

Dec 5, 2017

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on November 27, 2017, the Compensation Committee of the Board of...

Show 100  per
page

 [1](#) [2](#) [3](#) 



<https://investors.portola.com/news-releases?ID=2376001&c=198136&p=irol-newsArticle&l=100>